TRAF3 regulates the oncogenic proteins Pim2 and c-Myc to restrain survival in normal and malignant B cells.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
09 09 2019
Historique:
received: 17 05 2019
accepted: 23 08 2019
entrez: 11 9 2019
pubmed: 11 9 2019
medline: 3 11 2020
Statut: epublish

Résumé

TRAF3 is a versatile intracellular adapter protein with multiple context-specific roles. Uniquely in B cells, TRAF3 deficiency enhances survival and increases the risk of transformation, as loss of TRAF3 is observed in several types of B cell cancers. Here, we report a new mechanism for TRAF3 in the restraint of B cell survival. We found that TRAF3 deficiency was associated with induction of the pro-survival kinase Pim2 in mouse primary B cells and human malignant B cell lines. The increase in Pim2 was independent of NF-κB2 activation but was ameliorated with inhibition of STAT3 expression or function. TRAF3 deficiency also led to a Pim2-dependent increase in c-Myc protein levels and was associated with reduced c-Myc ubiquitination. TRAF3-deficient primary B cells were less sensitive to cell death induced by the Pim inhibitors SGI-1776 and TP-3654. Interestingly, human malignant B cell lines with low expression of TRAF3 were more sensitive to Pim inhibition-induced cell death. Combination treatment of TRAF3-deficient B cells and B cell tumor lines with c-Myc inhibitors enhanced their sensitivity to Pim inhibition, suggesting a possible therapeutic strategy. TRAF3 thus suppresses a Pim2-mediated B cell survival axis, which can be a potential target for treatment of B cell malignancies.

Identifiants

pubmed: 31501481
doi: 10.1038/s41598-019-49390-9
pii: 10.1038/s41598-019-49390-9
pmc: PMC6733949
doi:

Substances chimiques

MYC protein, human 0
PIM2 protein, human 0
Proto-Oncogene Proteins 0
Proto-Oncogene Proteins c-myc 0
STAT3 Transcription Factor 0
TNF Receptor-Associated Factor 3 0
Protein Serine-Threonine Kinases EC 2.7.11.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

12884

Subventions

Organisme : NIAID NIH HHS
ID : T32 AI007485
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES005605
Pays : United States
Organisme : BLRD VA
ID : I01 BX001702
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007533
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007337
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA097274
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA086862
Pays : United States

Commentaires et corrections

Type : ErratumIn

Références

Blood. 2009 Nov 5;114(19):4150-7
pubmed: 19734450
Blood. 2015 Feb 5;125(6):999-1005
pubmed: 25468570
J Immunol. 2011 Jan 1;186(1):143-55
pubmed: 21084666
Front Immunol. 2013 Dec 20;4:477
pubmed: 24391649
Biomedicine. 1975 Jul;22(4):276-84
pubmed: 179629
Immunity. 2008 Mar;28(3):391-401
pubmed: 18313334
Leukemia. 2012 May;26(5):1122-7
pubmed: 22033491
Cell Rep. 2015 May 5;11(5):715-26
pubmed: 25921526
Nat Rev Immunol. 2009 Jul;9(7):491-502
pubmed: 19521398
J Immunol. 2015 Aug 1;195(3):953-64
pubmed: 26116508
J Immunol. 1986 Jan;136(1):348-56
pubmed: 2415625
Immunity. 1996 Nov;5(5):407-15
pubmed: 8934568
J Immunol. 2008 May 1;180(9):5794-8
pubmed: 18424697
J Hematol Oncol. 2014 Dec 10;7:95
pubmed: 25491234
Blood. 1987 May;69(5):1307-14
pubmed: 3567358
Hematology Am Soc Hematol Educ Program. 2013;2013:575-83
pubmed: 24319234
Cell. 2011 Sep 16;146(6):904-17
pubmed: 21889194
Front Immunol. 2018 Sep 24;9:2161
pubmed: 30319624
Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):1032-7
pubmed: 26755589
J Biol Chem. 2003 Nov 14;278(46):45358-67
pubmed: 12954615
Blood. 2011 Nov 17;118(20):5517-27
pubmed: 21937691
Sci Rep. 2016 Oct 18;6:35349
pubmed: 27752131
Blood. 2015 May 14;125(20):3039-40
pubmed: 25838347
Blood Cancer J. 2015 Jul 17;5:e325
pubmed: 26186558
PLoS One. 2014 Apr 16;9(4):e95020
pubmed: 24740248
Blood Adv. 2017 Dec 18;1(27):2712-2723
pubmed: 29296923
Semin Hematol. 2015 Apr;52(2):97-106
pubmed: 25805589
Nat Immunol. 2014 Sep;15(9):866-74
pubmed: 25029551
Cancer Res. 2008 May 1;68(9):3077-80; discussion 3080
pubmed: 18451130
Oncogene. 2008 Aug 14;27(35):4809-19
pubmed: 18438430
Blood. 1989 Mar;73(4):1020-7
pubmed: 2784066
Cancer Res. 1999 Apr 1;59(7 Suppl):1773s-1777s
pubmed: 10197595
Immunity. 1999 Dec;11(6):709-19
pubmed: 10626893
Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16669-74
pubmed: 21949397
Clin Cancer Res. 2015 Jan 1;21(1):113-22
pubmed: 25009295
Nat Cell Biol. 2004 Apr;6(4):308-18
pubmed: 15048125
Cancer Res. 2003 Mar 15;63(6):1270-9
pubmed: 12649187
Int J Cancer. 1985 Aug 15;36(2):241-6
pubmed: 3926660
PLoS One. 2013;8(3):e60298
pubmed: 23555950
Leukemia. 2011 Jul;25(7):1182-8
pubmed: 21475253
J Immunol. 2015 Jan 1;194(1):334-48
pubmed: 25422508
Cancer Sci. 2015 Jun;106(6):718-25
pubmed: 25854938
Cancer Res. 2007 Oct 15;67(20):9762-70
pubmed: 17942906
EMBO Rep. 2015 Mar;16(3):280-96
pubmed: 25680965
Front Immunol. 2018 Sep 20;9:2111
pubmed: 30294322
Blood. 2012 Sep 20;120(12):2450-3
pubmed: 22806891
Leukemia. 2014 Aug;28(8):1725-1735
pubmed: 24518206
Sci Signal. 2015 Sep 01;8(392):ra88
pubmed: 26329582
Immunity. 2006 Sep;25(3):403-15
pubmed: 16973390
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Blood. 2013 Aug 29;122(9):1610-20
pubmed: 23818547
J Immunol. 2003 Jun 15;170(12):5851-60
pubmed: 12794110
Neoplasia. 2014 May;16(5):403-12
pubmed: 24953177
Blood. 2004 Apr 15;103(8):3175-84
pubmed: 15070700
Blood. 2008 Jan 15;111(2):750-60
pubmed: 17942753
Immunity. 2007 Aug;27(2):253-67
pubmed: 17723217
J Leukoc Biol. 2016 Nov;100(5):919-926
pubmed: 27154354
Genes Dev. 2003 Aug 1;17(15):1841-54
pubmed: 12869584
Science. 2001 Mar 16;291(5511):2162-5
pubmed: 11251123
F1000Res. 2017 Dec 18;6:2142
pubmed: 29399323
Cold Spring Harb Perspect Biol. 2010 Jun;2(6):a000109
pubmed: 20516126
N Y State J Med. 1968 Aug 1;68(15):2054-60
pubmed: 5243066

Auteurs

Amy L Whillock (AL)

Department of Microbiology & Immunology, University of Iowa, Iowa City, IA, USA.
Immunology Graduate Program, University of Iowa, Iowa City, IA, USA.
Medical Scientist Training Program, University of Iowa, Iowa City, IA, USA.
Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.

Nurbek Mambetsariev (N)

Department of Microbiology & Immunology, University of Iowa, Iowa City, IA, USA.
Immunology Graduate Program, University of Iowa, Iowa City, IA, USA.
Medical Scientist Training Program, University of Iowa, Iowa City, IA, USA.
Northwestern Memorial Hospital, Chicago, IL, USA.

Wai W Lin (WW)

Department of Microbiology & Immunology, University of Iowa, Iowa City, IA, USA.
Immunology Graduate Program, University of Iowa, Iowa City, IA, USA.
Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA, USA.

Laura L Stunz (LL)

Department of Microbiology & Immunology, University of Iowa, Iowa City, IA, USA.
Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.

Gail A Bishop (GA)

Department of Microbiology & Immunology, University of Iowa, Iowa City, IA, USA. gail-bishop@uiowa.edu.
Internal Medicine, University of Iowa, Iowa City, IA, USA. gail-bishop@uiowa.edu.
Immunology Graduate Program, University of Iowa, Iowa City, IA, USA. gail-bishop@uiowa.edu.
Medical Scientist Training Program, University of Iowa, Iowa City, IA, USA. gail-bishop@uiowa.edu.
Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA. gail-bishop@uiowa.edu.
VA Medical Center, Iowa City, IA, USA. gail-bishop@uiowa.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH